ReviewJournal of molecular and cellular cardiology2011
Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits.
Review in Journal of molecular and cellular cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Comprehensive Insights into Mechanisms for Ventricular Remodeling in Right Heart Failure.Reviews in cardiovascular medicine · 2024Review
- Paeoniflorin-6'O-benzene sulfonate suppresses fibroblast-like synoviocytes proliferation and migration in rheumatoid arthritis through regulating GRK2-Gβγ interaction.Experimental and therapeutic medicine · 2022Article
- β-Adrenergic receptor, an essential target in cardiovascular diseases.Heart failure reviews · 2020Review
- Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.Trends in endocrinology and metabolism: TEM · 2017Review
- Medium-chain fatty acids modulate myocardial function via a cardiac odorant receptor.Basic research in cardiology · 2017Article
- From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.Heart, lung & circulation · 2016Review
- Cardiac Fibrosis: The Fibroblast Awakens.Circulation research · 2016Review
- Regulation of Fc∈RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain.The Journal of biological chemistry · 2014Article
- Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression.Journal of the American College of Cardiology · 2014Article
- Heart failure-specific changes in protein kinase signalling.Pflugers Archiv : European journal of physiology · 2014Review
- Pathological ventricular remodeling: mechanisms: part 1 of 2.Circulation · 2013Review
- Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics.Trends in pharmacological sciences · 2013Review
- Inhibition of the ethanol-induced potentiation of α1 glycine receptor by a small peptide that interferes with Gβγ binding.The Journal of biological chemistry · 2012Article
- G-protein coupled receptor resensitization-appreciating the balancing act of receptor function.Current molecular pharmacology · 2012Article
- Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches.Drug discovery today. Disease models · 2012Article
- Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration.Journal of molecular and cellular cardiology · 2011Review
- Regulators of G-protein signaling in the heart and their potential as therapeutic targets.Circulation research · 2011Review
- G protein coupled receptor kinases as therapeutic targets in cardiovascular disease.Circulation research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Heart failure (HF) is devastating disease with poor prognosis. Elevated sympathetic nervous system activity and outflow, leading to pathologic attenuation and desensitization of β-adrenergic receptors (β-ARs) signaling and responsiveness, are salient characteristic of HF progression. These pathologic effects on β-AR signaling and HF progression occur in part due to Gβγ-mediated signaling, including recruitment of receptor desensitizing kinases such as G-protein coupled receptor (GPCR) kinase 2 (GRK2) and phosphoinositide 3-kinase (PI3K), which subsequently phosphorylate agonist occupied GPCRs. Additionally, chronic GPCR signaling signals chronically dissociated Gβγ subunits to interact with multiple effector molecules that activate various signaling cascades involved in HF pathophysiology. Importantly, targeting Gβγ signaling with large peptide inhibitors has proven a promising therapeutic paradigm in the treatment of HF. We recently described an approach to identify small molecule Gβγ inhibitors that selectively block particular Gβγ functions by specifically targeting a Gβγ protein-protein interaction "hot spot." Here we describe their effects on Gβγ downstream signaling pathways, including their role in HF pathophysiology. We suggest a promising therapeutic role for small molecule inhibition of pathologic Gβγ signaling in the treatment of HF. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.